Larimar Therapeutics Shows Promise in Friedreich’s Ataxia Treatment

Larimar Therapeutics, Inc. ( (LRMR) ) has released its Q3 earnings. Here is a breakdown of the information Larimar Therapeutics, Inc. presented to its investors.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound, nomlabofusp, targeting Friedreich’s ataxia. In its third quarter 2025 financial results, Larimar reported significant progress in its open label study, showing promising data on nomlabofusp’s potential to alter the disease course of Friedreich’s ataxia. The study demonstrated consistent improvements in clinical outcomes and increased skin frataxin levels, although some participants experienced anaphylaxis, prompting a modified starting dose regimen to mitigate risks. Financially, the company reported a net loss of $47.7 million for the quarter, attributed to increased research and development expenses, particularly in nomlabofusp manufacturing costs. Looking ahead, Larimar aims to submit a Biologics License Application seeking accelerated approval in the second quarter of 2026, with a focus on advancing nomlabofusp as a potential disease-modifying therapy for Friedreich’s ataxia.